13 May 2021 - The revised agenda for the July 2021 PBAC meeting notes seven medicines/medicinal preparations for review under the new process.
The seven medicines/medical preparations are:
The list is odd given it includes medicines recommended more than five years ago and omits others recommended in more recent times. The list does not include the recommendations for:
There are many more.
The inclusion for ramucirumab seems odd given the PBAC's rejection of Eli Lilly's resubmission in July 2019. The Committee did not recommend a change to the basis of its March 2018 recommendation for ramucirumab for use in combination with paclitaxel for the treatment of patients with gastric or gastro-oesophageal junction adenocarcinoma.